Podcasts about antipdl1

GRACEcast Lung Cancer Audio

Play Episode Listen Later Dec 10, 2013 7:06

Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

cancer lung lung cancer immunotherapy pd l1 nivolumab squamous pd1 spigel gracecast cancergrace antipd1 antipdl1

Squamous Lung Cancer, Part 4: Immunotherapy (audio)

Play Episode Listen Later Dec 10, 2013 7:06

Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

cancer lung lung cancer immunotherapy pd l1 nivolumab squamous pd1 spigel gracecast cancergrace antipd1 antipdl1

Squamous Lung Cancer, Part 4: Immunotherapy (video)

Play Episode Listen Later Dec 10, 2013 7:07

Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

cancer lung lung cancer immunotherapy pd l1 nivolumab squamous pd1 spigel gracecast cancergrace antipd1 antipdl1

Squamous Lung Cancer, Part 4: Immunotherapy (audio)

Play Episode Listen Later Dec 10, 2013 7:06

Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

cancer lung lung cancer immunotherapy pd l1 nivolumab squamous pd1 spigel gracecast cancergrace antipd1 antipdl1

Squamous Lung Cancer, Part 4: Immunotherapy (video)

Play Episode Listen Later Dec 10, 2013 7:07

Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

cancer lung lung cancer immunotherapy pd l1 nivolumab squamous pd1 spigel gracecast cancergrace antipd1 antipdl1

How should we integrate new immunotherapies into treatment strategies for lung cancer?

Play Episode Listen Later Jul 4, 2013 4:17

Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.

west therapy cancer institute cleveland swedish clinic drs immune integrate checkpoint lung cancer immunotherapy asco moffitt inhibitor pinder nsclc adjuvant treatment strategies pennell nivolumab jack west gracecast cancergrace antipd1 antipdl1

How should we integrate new immunotherapies into treatment strategies for lung cancer?

Play Episode Listen Later Jul 4, 2013 4:17

Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.

west therapy cancer institute cleveland swedish clinic drs immune integrate checkpoint lung cancer immunotherapy asco moffitt inhibitor pinder nsclc adjuvant treatment strategies pennell nivolumab jack west gracecast cancergrace antipd1 antipdl1

How should we integrate new immunotherapies into treatment strategies for lung cancer?

Play Episode Listen Later Jul 4, 2013 4:17

Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.

west therapy cancer institute cleveland swedish clinic drs immune integrate checkpoint lung cancer immunotherapy asco moffitt inhibitor pinder nsclc adjuvant treatment strategies pennell nivolumab jack west gracecast cancergrace antipd1 antipdl1

Can we harness our immune system to fight NSCLC?

Play Episode Listen Later Jun 19, 2013 8:45

Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

west cancer institute cleveland swedish clinic drs harness immune system immune checkpoint immunotherapy asco moffitt inhibitor pinder nsclc pennell pd l1 nivolumab jack west pd1 spigel gracecast cancergrace antipd1 antipdl1

Can we harness our immune system to fight NSCLC?

Play Episode Listen Later Jun 19, 2013 8:45

Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

west cancer institute cleveland swedish clinic drs harness immune system immune checkpoint immunotherapy asco moffitt inhibitor pinder nsclc pennell pd l1 nivolumab jack west pd1 spigel gracecast cancergrace antipd1 antipdl1

Can we harness our immune system to fight NSCLC?

Play Episode Listen Later Jun 19, 2013 8:45

Drs. Mary Pinder, Nate Pennell, and Jack West discuss promising work on immune checkpoint inhibitors such as MPPL-3280A, an anti-PDL1 immune-based therapy, and anti-PD1 therapy nivolumab, in advanced NSCLC.

west cancer institute cleveland swedish clinic drs harness immune system immune checkpoint immunotherapy asco moffitt inhibitor pinder nsclc pennell pd l1 nivolumab jack west pd1 spigel gracecast cancergrace antipd1 antipdl1

Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

Play Episode Listen Later Mar 25, 2013 1:50

Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

university therapy stanford stanford university treating pathways targeted promising lung cancer immunotherapy biomarker inhibitor mek new agents wakelee gracecast cancergrace selumetinib antiangiogenesis antipd1 antipdl1 metmab

Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

Play Episode Listen Later Mar 25, 2013 1:50

Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

university therapy stanford stanford university treating pathways targeted promising lung cancer immunotherapy biomarker inhibitor mek new agents wakelee gracecast cancergrace selumetinib antiangiogenesis antipd1 antipdl1 metmab

Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

Play Episode Listen Later Mar 25, 2013 1:50

Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

university therapy stanford stanford university treating pathways targeted promising lung cancer immunotherapy biomarker inhibitor mek new agents wakelee gracecast cancergrace selumetinib antiangiogenesis antipd1 antipdl1 metmab

Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?

Play Episode Listen Later Mar 7, 2013 2:07

Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

university colorado pennsylvania targets drs mutation molecular therapies langer marker lung cancer immunotherapy near future her2 braf subgroups ross camidge cancer clinic gracecast cancergrace camidge antipd1 antipdl1

Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?

Play Episode Listen Later Mar 7, 2013 2:07

Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

university colorado pennsylvania targets drs mutation molecular therapies langer marker lung cancer immunotherapy near future her2 braf subgroups ross camidge cancer clinic gracecast cancergrace camidge antipd1 antipdl1

Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?

Play Episode Listen Later Mar 7, 2013 2:07

Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

university colorado pennsylvania targets drs mutation molecular therapies langer marker lung cancer immunotherapy near future her2 braf subgroups ross camidge cancer clinic gracecast cancergrace camidge antipd1 antipdl1

Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?

Play Episode Listen Later Mar 1, 2013 1:36

Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

university therapy vaccines optimistic mutation lung cancer mcmaster immunotherapy cancer treatments kras mek novel therapies gracecast cancergrace selumetinib antipd1 antipdl1

Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?

Play Episode Listen Later Mar 1, 2013 1:36

Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

university therapy vaccines optimistic mutation lung cancer mcmaster immunotherapy cancer treatments kras mek novel therapies gracecast cancergrace selumetinib antipd1 antipdl1

Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?

Play Episode Listen Later Mar 1, 2013 1:36

Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

university therapy vaccines optimistic mutation lung cancer mcmaster immunotherapy cancer treatments kras mek novel therapies gracecast cancergrace selumetinib antipd1 antipdl1

ASCO 2012 LC Highlights: Dr. Joel Neal on Anti-PD-1 Immunotherapy for Advanced NSCLC (video)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Sep 5, 2012 7:41

Dr. Joel Neal describes the very encouraging data on anti-PD-1 immunotherapy with BMS-936558/MDX-1106 in patients with advanced non-small cell lung cancer (NSCLC).

pd immunotherapy asco bms nsclc mdx gracecast cancergrace antipd1 antipdl1

ASCO 2012 LC Highlights: Dr. Joel Neal on Anti-PD-1 Immunotherapy for Advanced NSCLC (audio)

Play Episode Listen Later Sep 4, 2012 7:40

Dr. Joel Neal describes the very encouraging data on anti-PD-1 immunotherapy with BMS-936558/MDX-1106 in patients with advanced non-small cell lung cancer (NSCLC).

pd immunotherapy asco bms nsclc mdx gracecast cancergrace antipd1 antipdl1

Immunotherapy for Lung Cancer: Yervoy, anti-PD-1, Reolysin, & Talactoferrin by Dr. J. Brahmer (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Jun 14, 2012 23:36

Dr. Julie Brahmer reviews science and early trial results for immunotherapies for lung cancer ranging from cancer vaccines to anti-cancer viruses.

cancer vaccines lung lung cancer immunotherapy nsclc pd l1 tlf pd1 ipilimumab ctla4 gracecast yervoy cancergrace brahmer nonsmall antipd1 antipdl1

Immunotherapy for Lung Cancer: Yervoy, anti-PD-1, Reolysin, & Talactoferrin by Dr. J. Brahmer (video)